Skip to contentA
Amphastar Pharmaceuticals, Inc.
A
AMPHAmphastar Pharmaceuticals, Inc. Q3 2020 · 10-Q
Revenue$83.43M$83.43M+4.1% vs Q3 2019 Net Income$3.92M$3.92M+199.2% vs Q3 2019 EPS Diluted$0.08$0.08+166.7% vs Q3 2019 Gross Profit$36,508,000+3.6% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Amphastar Pharmaceuticals, Inc. · CIK 1297184 · Engraved from SEC EDGAR
Operating Cash Flowderived$8,807,000N/M Free Cash Flowderived$3,176,000N/M Margins · derivedGross margin43.8%−0.2 pt vs Q3 2019
Operating margin4.2%+1.2 pt vs Q3 2019
Net margin4.7%+3.1 pt vs Q3 2019
ended Sep 30, 2020 · filed Nov 6, 2020 · 37 d after period end